Top Markets
#1 NEW X CEO IS BACK NEW X CEO IS BACK +190,916.81%
#2 Beta Finance Beta Finance +8,977.34%
#3 Velas Velas +461.19%
#4 Tribe Tribe +73.83%
#5 Orochi Network Orochi Network +51.29%
#6 Chainbase Chainbase +40.86%
#7 BabyBoomToken BabyBoomToken +34.51%
#8 Freysa AI Freysa AI +33.79%
#9 Block Street Block Street +28.93%
#10 Chrema Coin Chrema Coin +27.48%
Coin of the day
NEW X CEO IS BACK NEW X CEO IS BACK
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Nuformix plc Nuformix plc

Nuformix plc

NFX
Classement en actions #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Prix de l'action
$0.00244926
Capitalisation boursière
$51.67K
Changement (1 jour)
5.88%
Changement (1 an)
110.15%
Pays
GB
Échange Nuformix plc (NFX)

Catégorie

Healthcare
Ratio P/B pour Nuformix plc (NFX)
Ratio P/B au March 2026 TTM : 5.52
Selon les derniers rapports financiers et le cours de l'action de Nuformix plc, le ratio cours/valeur comptable actuel (TTM) est 5.52. À la fin de 2024, le ratio P/B était de 0.64.
Historique du ratio P/B pour Nuformix plc de 2014 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
2026 (TTM) 5.52 6.74%
2025 5.17 703.62%
2024 0.64 44.29%
2023 0.45 -63.79%
2022 1.23 -46.40%
2021 2.30 -42.90%
2020 4.02 28.15%
2019 3.14 93.67%
2018 1.62 -108.69%
2017 -18.66 -793.31%
2016 2.69 0.00%
2014 0.00 0.00%
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 5.6573 2.51%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3842 15.68%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 2.4551 -55.51%
US
UCB SA UCB SA
UCB SA
UCB.BR
 4.364 -20.92%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5504 -53.79%
AU